DexCom (NASDAQ:DXCM) Reaches New 12-Month Low - Here's Why

Shares of DexCom, Inc. (NASDAQ:DXCM - Get Free Report) hit a new 52-week low during trading on Thursday . The company traded as low as $61.74 and last traded at $62.24, with a volume of 1724552 shares trading hands. The stock had previously closed at $68.14.

Analyst Ratings Changes

DXCM has been the topic of several recent analyst reports. Cfra Research upgraded shares of DexCom to a "hold" rating in a research note on Friday, March 21st. Wells Fargo & Company reiterated an "overweight" rating on shares of DexCom in a research report on Saturday, March 8th. Baird R W upgraded shares of DexCom from a "hold" rating to a "strong-buy" rating in a research report on Thursday, January 16th. Morgan Stanley lifted their target price on shares of DexCom from $75.00 to $82.00 and gave the company an "equal weight" rating in a research report on Friday, February 14th. Finally, Canaccord Genuity Group increased their price target on shares of DexCom from $99.00 to $103.00 and gave the stock a "buy" rating in a report on Friday, February 14th. Five research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $99.82.

DexCom Stock Down 1.5 %

The stock has a market capitalization of $23.80 billion, a PE ratio of 42.44, a P/E/G ratio of 2.30 and a beta of 1.50. The firm has a 50 day moving average of $79.63 and a two-hundred day moving average of $76.90. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59.

Remove Ads

DexCom (NASDAQ:DXCM - Get Free Report) last issued its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. Equities research analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current year.

Insider Activity at DexCom

In other news, EVP Jereme M. Sylvain sold 2,090 shares of the company's stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $181,641.90. Following the sale, the executive vice president now owns 83,526 shares in the company, valued at approximately $7,259,244.66. This represents a 2.44 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Jacob Steven Leach sold 2,634 shares of the business's stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $228,920.94. Following the sale, the chief operating officer now owns 268,644 shares of the company's stock, valued at approximately $23,347,850.04. The trade was a 0.97 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 105,009 shares of company stock worth $8,044,178. Corporate insiders own 0.30% of the company's stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Geode Capital Management LLC boosted its stake in DexCom by 0.6% in the fourth quarter. Geode Capital Management LLC now owns 9,993,698 shares of the medical device company's stock valued at $775,256,000 after acquiring an additional 56,094 shares during the period. Jennison Associates LLC boosted its position in DexCom by 10.3% during the 4th quarter. Jennison Associates LLC now owns 7,643,757 shares of the medical device company's stock valued at $594,455,000 after purchasing an additional 710,858 shares during the period. Norges Bank acquired a new stake in shares of DexCom in the 4th quarter worth about $385,367,000. Northern Trust Corp boosted its stake in DexCom by 22.2% during the 4th quarter. Northern Trust Corp now owns 4,146,249 shares of the medical device company's stock valued at $322,454,000 after purchasing an additional 753,857 shares during the period. Finally, Groupama Asset Managment grew its position in DexCom by 1.1% in the 3rd quarter. Groupama Asset Managment now owns 2,851,556 shares of the medical device company's stock worth $1,912,000 after purchasing an additional 31,358 shares during the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.